CONCORD, Calif. & BOSTON--(BUSINESS WIRE)--

Sempresto, Inc., a medical device company pioneering smartphone-integrated rescue drug delivery, today announced the acquisition of all patents and related physical and digital assets from inventor Steven A. Friedman. Friedman’s innovations—focused on novel mechanisms and enhanced safety features for mobile device-integrated autoinjectors—provide key building blocks for Sempresto’s next-generation drug delivery platforms. This strategic acquisition further expands Sempresto’s intellectual property portfolio in cellphone-mounted and connected drug delivery systems.

“Friedman’s broad and innovative platform supports our strategic objectives and enhances our leadership position in cellphone-based drug delivery,” said Elizabeth Reczek, PhD, CEO of Sempresto. “By integrating his work into our expanding portfolio, we are accelerating development of technologies that will redefine how patients access life-saving medications.”

“I am pleased that my work, with its focus on safety and portability of lifesaving medications, will be advanced by Sempresto,” said Steven A. Friedman. “The leadership team—with their deep expertise and personal experience with severe allergies—are the right group to bring this vision forward and ensure it reaches the patients who need it.”

With this transaction, Sempresto reinforces its position as leader in the development of smartphone-mounted, always-connected autoinjectors that improve patient preparedness and empower those living with severe allergies and other acute conditions.

About Sempresto, Inc.

Sempresto is led by an experienced team of life science and medical technology professionals, many with firsthand experience managing severe allergies. The company’s mission — “Always There, Always Connected” — drives its development of innovative solutions that ensure immediate access to life-saving medicines. Sempresto’s flagship product, a smartphone-integrated epinephrine autoinjector, represents a transformative leap forward in preparedness for severe allergy sufferers and other acute conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119531452/en/

Source: Sempresto, Inc.